Shounak S. Jagdale

Shounak S. Jagdale

Auto-generated profile, based on publicly available information

Shounak S. Jagdale

Mutualisms Research Group, Max Planck Institute for Biology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
RJRakesh S. Joshi
Rakesh S. Joshi
SJShounak S. Jagdale
Shounak S. Jagdale
SBSneha B. Bansode
Sneha B. Bansode
SSS. Shiva Shankar
S. Shiva Shankar
MTMeenakshi B. Tellis
Meenakshi B. Tellis
MKMAHESH KULKARNI
MAHESH KULKARNI
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts are going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (MPro) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of MPro, we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae MPro in five clusters specific to viral hosts. This clustering was corroborated with the comparison of MPro structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 MPro. In agreement with this, we performed screening of ∼7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 MPro as the primary target. We identified several natural molecules like δ-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 MPro. Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection.

5 September 2019 in Journal of Pest Science
Verified
Journal Article
Closed access
PDF file
Amalendu GhoshAmalendu Ghosh
Amalendu Ghosh
SJShounak S. Jagdale
Shounak S. Jagdale
BABasavaraj
Basavaraj
Ralf Georg DietzgenRalf Georg Dietzgen
Ralf Georg Dietzgen
RJRakesh Kumar Jain
Rakesh Kumar Jain


6 January 2018 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SJShounak S. Jagdale
Shounak S. Jagdale
RJRakesh S. Joshi
Rakesh S. Joshi

1 June 2019 in Current Opinion in Insect Science
Verified
Journal Article
Closed access
SJShounak S Jagdale
Shounak S Jagdale
RJRakesh Joshi
Rakesh Joshi

12 September 2017
Verified
Book Chapter
Closed access
PDF file
SJShounak Jagdale
Shounak Jagdale
SBSneha Bansode
Sneha Bansode
RJRakesh Joshi
Rakesh Joshi